Novartis AG Sponsored ADR pharmaceutical (NVS.US) Class 1 new drug approved for clinical use in rheumatoid arthritis.

On May 8th, the official website of China's Drug Evaluation Center showed that Novartis AG Sponsored ADR drug PIT565, a new type 1 drug, has been approved for clinical use for rheumatoid arthritis. PIT565 is a novel CD3/CD19/CD2 triple antibody, which, compared to CD3 bispecific antibodies, can overcome T cell exhaustion and increase patients' response depth and duration by co-stimulating with CD2 through PIT565. The drug was first applied for clinical trials domestically in November 24th, 25 and approved for clinical use in January 25 for relapsed and/or refractory B-cell malignancies. In February 25, it was approved for clinical use again for systemic lupus erythematosus, achieving a cross-border from cancer to autoimmune diseases. Currently, both indications have started Phase I clinical trials and are recruiting patients. Screenshot source: CDE official website Source of image: Insight database